openPR Logo
Press release

Globally, More than 100+ Key Companies are working in the Multiple Myeloma Pipeline Landscape

08-08-2022 07:22 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Multiple Myeloma Pipeline

Multiple Myeloma Pipeline

DelveInsight's Multiple Myeloma Pipeline Insights 2022," report provides comprehensive insights about 100+ companies and 130+ pipeline drugs in Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The Multiple Myeloma Pipeline report also provides the inactive products analysis (dormant and terminated) along with the reasons for dormancy and discontinuation, wherever available. This report provides detailed profiles of the pipeline assets and comparative analysis of clinical and non-clinical stage products.

Multiple Myeloma Overview
Multiple myeloma is a clonal plasma cell proliferative disorder characterized by the abnormal increase of monoclonal paraprotein leading to evidence of specific end-organ damage. Unchecked, the excess production of these plasma cells can ultimately lead to specific end-organ damage. Most commonly, this is seen when at least one of the following clinical manifestations are present: hypercalcemia, renal dysfunction, anemia, or bone pain accompanied by lytic lesions.

Download Sample Report- https://www.delveinsight.com/sample-request/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Multiple Myeloma Pipeline Analysis
The report provides insights into:
• The report provides detailed insights about companies that are developing therapies in the Multiple myeloma Market.
• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple myeloma treatment.
• Multiple myeloma key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Multiple myeloma Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple myeloma market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Multiple myeloma Emerging Drugs
• Elranatamab: Pfizer
• Felzartamab: Janssen Pharmaceutical

Multiple Myeloma Therapeutics Analysis
There are approx. 100+ key companies which are developing the therapies Multiple myeloma. The companies which have their Multiple myeloma drug candidates in the most advanced stage, i.e phase III include Janssen Pharmaceuticals

Multiple Myeloma Pipeline Phases
DelveInsight's report covers around 130+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Multiple Myeloma Pipeline Molecule Type
Products have been categorized under various Molecule types such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Multiple Myeloma Pipeline Companies include-
• Janssen/Pharmacyclics
• Novartis
• Incyte Corporation
• Gracell Biotechnology
• SpringWorks Therapeutics
• Sana Biotechnology
• Cytovia Therapeutics
• Pfizer
• MorphoSys
• Biokine Therapeutics
• Arcellx
• Rapa Therapeutics
• iTeos Therapeutics
• Sorrento Therapeutics
• CARsgen
• Ascentage Pharma
• Cartesian Therapeutics
• Bristol-Myers Squibb
• Juno Therapeutics
• Nanjing IASO Biotherapeutics
• Arch Oncology
• Oncoceutics
• TeneoBio
• Nerviano Medical Sciences, and several others

Multiple Myeloma Pipeline Therapies
• Elranatamab
• PHE885
• STI-1492
• IMC 3253, and several others

Request Sample Report- https://www.delveinsight.com/sample-request/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Multiple myeloma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Multiple myeloma- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Venetoclax: AbbVie
9. Mid Stage Products (Phase II)
10. PHE885: Novartis
11. Early Stage Products (Phase I/II)
12. ONC 201: Oncoceutics
13. Early Stage Products (Phase I)
14. TNB 383B: TeneoBio
15. Inactive Products
16. Multiple myeloma Key Companies
17. Multiple myeloma Key Products
18. Multiple myeloma- Unmet Needs
19. Multiple myeloma- Market Drivers and Barriers
20. Multiple myeloma- Future Perspectives and Conclusion
21. Multiple myeloma Analyst Views
22. Multiple myeloma Key Companies
23. Appendix

Do you have any query related to the report? If yes, visit here- https://www.delveinsight.com/report-store/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Contact Us
Yash
info@delveinsight.com

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Globally, More than 100+ Key Companies are working in the Multiple Myeloma Pipeline Landscape here

News-ID: 2699846 • Views: 324

More Releases from DelveInsight Business Research

Bipolar Depression Pipeline Drugs and Companies Insight Report: Analysis of Clin …
Bipolar Depression pipeline constitutes 6+ key companies continuously working towards developing 6+ Bipolar Depression treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. Bipolar Depression Overview Bipolar disorder is a disabling chronic disease in which depression usually presents a higher risk of long-term functional impairment than mania. Persistent depression does not have a known cause. As with bipolar disorder, depression has hereditary
Neuromyelitis Optica Spectrum Disorder Pipeline Drugs and Companies Insight Repo …
Neuromyelitis Optica Spectrum Disorder pipeline constitutes 15+ key companies continuously working towards developing 15+ Neuromyelitis Optica Spectrum Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. Neuromyelitis Optica Spectrum Disorder Overview Neuromyelitis Optica Spectrum Disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and
Hemorrhoids Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, La …
Hemorrhoids pipeline constitutes 10+ key companies continuously working towards developing 10+ Hemorrhoids treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. Hemorrhoids Overview Hemorrhoids, also called piles, are swollen and inflamed veins around the anus or in lower rect#m. The two types of hemorrhoids are external hemorrhoids, which form under the skin around the anus, and internal hemorrhoids, which form in the
Cystic Fibrosis Pipeline Assessment (2022): In-depth Analysis of Clinical Trials …
Cystic Fibrosis pipeline constitutes 75+ key companies continuously working towards developing 80+ Cystic Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. Cystic Fibrosis Overview Cystic fibrosis (CF) is a recessive genetic disease caused by a mutation in the epithelial chloride channel-cystic fibrosis transmembrane conductance regulator (CFTR). CF is a predominant genetic disorder with a disease severity ranging from mild to

All 5 Releases


More Releases for Multiple

Global Multiple Sclerosis Market Size, Global Multiple Sclerosis Market Share, G …
The Global Multiple Sclerosis Market Size is majorly driven by the factors such as rising number of consolidations between the market players for exploring the untapped market opportunity across the world. Request for Sample of This Research Report @ https://bit.ly/2Nh6b4d Top Key Player:- Hoffmann-La Roche Ltd. Bayer Healthcare AG Teva Pharmaceuticals GlaxoSmithKline AbbVie Inc. Sonafi Pasteur Pfizer Inc. Merck & Company Novartis AG AB Science Opexa Multiple Sclerosis (MS) is a disease in which the insulating covers of nerves and spinal cord are
Develop business strategies Of Multiple Sclerosis Market
MarketResearchReports.Biz adds “Global Multiple Sclerosis Market Share, Size, Trends and Forecast Market Research Report” reports to its database. This report provides a strategic analysis of the Multiple Sclerosis and the growth estimates for the forecasted period. GlobalData's clinical trial report, Multiple Sclerosis Global Clinical Trials Review, H1, 2018" provides an overview of Multiple Sclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Sclerosis.
Thermoseal Group Multiple Award Winners
For the second year in a row, Thermoseal Group is the winner of the coveted Glass and Glazing Industry’s G-Award for ‘Component Supplier of the Year’ as announced at the prestigious Gala Dinner held at the Hilton on Park Lane Hotel in London on Friday 18 November 2016. This was a great day for Thermoseal Group who were also announced winners at two other awards events held that day
Reduce Headaches Updating Multiple Spreadsheets
Melbourne, Australia – DataMystic announces ExcelPipe 7.5, its enhanced mass-replacement utility for Microsoft Excel. Do you make the same change to a group of Excel Spreadsheets, over and over again? End of calendar year? End of financial year? And you know how tedious that is? ExcelPipe is a time-saving search and replace tool designed to work hand-in-hand with Microsoft Excel to change thousands of Spreadsheets automatically. It saves weeks of manual labor
Reduce Headaches Updating Multiple Documents
Reduce Headaches Updating Multiple Documents Melbourne, Australia – DataMystic announces WordPipe 9.4, its enhanced mass-replacement utility for Microsoft Word. Do you make the same change to a group of Word documents, over and over again? And you know how tedious that is? WordPipe is a time-saving search and replace tool designed to work hand-in-hand with Microsoft Word to change thousands of documents automatically. It saves weeks of manual labor when links need changing,
Formulating Cosmetics For Multiple Markets
With all the regulatory information and expertise available, it’s worth considering the destination markets where you want to sell a product as the basis for the formulation you use. For example, when formulating products destined for the US market, you should consider the demands of federal and state legislation – in as many states as you want to sell into. If California is one of them, you need to know if